Navigation Links
KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM)
Date:1/22/2008

Potential NDA Approval for Gestiva(TM) Anticipated in Calendar 2008 Gestiva(TM), is Designated as an Orphan Drug by the FDA for the Prevention

of Preterm Birth in Singleton Pregnancies

ST. LOUIS, Jan. 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that it has entered into a definitive purchase agreement that gives KV full U.S. and worldwide rights to Gestiva(TM) (17-alpha hydroxyprogesterone caproate) upon approval of the pending Gestiva(TM) New Drug Application ("NDA").

The NDA for Gestiva(TM) is currently before the FDA, pending approval for use in the prevention of preterm birth in certain categories of pregnant women. The proposed indication is for to women with a history of at least one spontaneous preterm delivery (i.e., less than 37 weeks), who are pregnant with a single fetus. The FDA issued an "approvable" letter for Gestiva(TM) in October 2006, and a final approval is anticipated in late 2008. The FDA has granted an Orphan Drug Designation for Gestiva(TM).

KV is acquiring Gestiva(TM) from Massachusetts-based Hologic, Inc. for $82 million in cash, $7.5 million of which is payable at closing. The balance is payable upon final FDA approval and the production of launch quantities of Gestiva(TM). KV expects Gestiva(TM) to be additive to KV's earnings per share in the first 12 months following its launch.

"Gestiva(TM) marks an exciting and important extension to Ther-Rx's growing women's health franchise," said Marc S. Hermelin, Chairman of the Board and Chief Executive Officer of KV. "Our commitment to women's health is second-to-none in the industry and we believe the acquisition of Gestiva(TM), following the acquisition of our approved and soon-to-be-launched Evamist(TM)
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
2. Pharmaceutical market fails pregnant women; and more
3. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
4. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
5. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
9. Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes
10. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
11. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Health Advocate™, Inc., the ... subsidiary of West Corporation, is introducing its newest solution ... Costs and Enhance Quality. , The webinar will be ... ET and again at 2 PM ET. For more ... http://www.HealthAdvocate.com/Analytics or call 866.799.2655. , In an ...
(Date:7/25/2014)... could be treated more quickly after Manchester research ... and blood test on arrival, is effective in ... new study shows., The findings of a research ... Journal, could potentially make a huge difference to ... the most common reason for emergency hospital admission. ...
(Date:7/25/2014)... A probiotic that prevents obesity could be on ... in the gut inhibit weight gain, insulin resistance ... in mice, Vanderbilt University investigators have discovered. , ... to human," said senior investigator Sean Davies, Ph.D., ... most of the negative consequences of obesity in ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
(Date:7/25/2014)... -- Dietary changes can dramatically alter the balance of ... to a new study. These fluctuations could ... ease flare-ups for people with certain chronic illnesses, such ... the researchers said. Trillions of bacteria live in ... isn,t well understood, the Massachusetts Institute of Technology (MIT) ...
Breaking Medicine News(10 mins):Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2
... 2.1 Million Teens ... ... 2009 -- With an estimated 2,500 children ages 12 to 17 taking a prescription painkiller ... with MedSafe, the developers of a state-of-the-art medication lock-box, to curb the problem where it ...
... worker study suggests more potential hazards from the plastics ... to high levels of the controversial plastics chemical bisphenol ... including impotence and low sex drive, among Chinese factory ... researchers stressed that the workers were exposed to BPA ...
... ... is the inspiration for a new film which will find its way onto the ... ... event, the Molecular Medicine Tri-Conference (February 3-5, 2010) will feature inspirational Keynote John F. ...
... The Quigley Corporation, (Nasdaq: QGLY) , ... a conference call in which Ted Karkus, Chairman and CEO, will ... results and Q&A. , The conference call will be ... www.quigleyco.com ), at 11:00 AM (ET) on Thursday, November 12, ...
... LONDON, November 11 Extensive research conducted ... University of,Sheffield on the Simbionix PROcedure Rehearsal Studio(TM), was ... 2009 congress in Lisbon, Portugal. , ... year, is,the world,s first patient specific system to enable ...
... ... home or office using methods and products that are government-approved, but that won,t harm your ... Rhinebeck, ... The Natural Flu Protection Kit, the first product to emerge from the company’s partnership with ...
Cached Medicine News:Health News:D.A.R.E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 2Health News:D.A.R.E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 3Health News:BPA Tied to Impotence in Men 2Health News:BPA Tied to Impotence in Men 3Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 2Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 3Health News:The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 3Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 2Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 3
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... quarter financial results on Tuesday, July 29, 2014, after the ... followed by a conference call with the investment community at ... be Robert A. Bradway , chairman and chief executive ... Live audio of the conference call will be simultaneously ...
(Date:7/24/2014)... , July 24, 2014 Many new dentists who ... do to ensure that their practice will be a success. ... basic supplies they use the most can make all the ... dentists have recently discovered that purchasing discount dental supplies ... According to successful dentists across the ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2Dental Supplies Online is Key to Dental Success...Really! 2
... 1, 2012 The FDA and representatives from the ... on proposed recommendations for the third reauthorization of a ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The recommendations would authorize the ... five years, plus adjustments for inflation. Details of the ...
... Corporation (NYSE: BSX ) announces first ... PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent ... the new device was performed by Professor Antonio ... at Columbus Hospital and San Raffaele Hospital in ...
Cached Medicine Technology:FDA and Industry Reach Agreement in Principle on Medical Device User Fees 2FDA and Industry Reach Agreement in Principle on Medical Device User Fees 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 2Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: